Brief Answer:
explained

Detailed Answer:
Hello and Welcome

I appreciate your concern.

Routine imaging is not required in all patients in whom ovarian cancer is highly suggested. If diagnostic uncertainty is present, a pelvic ultrasound or CT scan of the abdomen and pelvis is warranted.Chest radiographs are common and considered routine.

MRI can increase the specificity of imaging evaluation in cases where the ultrasound appearance of a lesion is indeterminate.

When imaging studies demonstrate an adnexal mass, the decision whether to observe the patient with repeat imaging or to proceed to surgical evaluation must take into account not only the imaging characteristics but also the patient's medical history, physical examination results, and cancer antigen 125 (CA125) level. Tumor markers such as CA125 are not good discriminators of benign lesions from malignant lesions in premenopausal women but have better accuracy in postmenopausal women.

Although CA125 is elevated in 83% of women with epithelial ovarian cancer, it is elevated in only 50% of those with stage I disease.

No marker is completely specific; therefore, diagnostic immunohistochemistry testing must be used in conjunction with morphologic and clinical findings.

While this test is not generally regarded as useful for large scale screening by the medical community, a high value may be an indication that the woman should receive further diagnostic screening or treatment. Normal values range from 0 to 35 (U/mL).
So, your value is normal and the doubling of ca 125 is not significant
Yes ca 125 levels may fluctuate in postmenopausal women but that is not a matter of concern as long as it remains in the normal range


Elevated levels in post-menopausal women are usually an indication that further screening is necessary. In pre-menopausal women, the test is less reliable as values are often elevated due to a number of non-cancerous causes, and a value above 35 is not necessarily a cause for concern.

In a patient who is clinically selected for testing due to the presence of an adnexal/pelvic mass, CA-125 has great utility to differentiate benign from malignant processes. In a post-menopausal woman with a palpable adnexal mass and CA-125 level greater than 65 U/mL, the positive predictive value is >95% for ovarian malignancy. .




Let me know if you have any query

wishing you best of health

Thanks

---

Brief Answer:
explained

Detailed Answer:
Hello again

The test kits can vary and so do the ranges, there needs to be a significant rise, which isn't the issue in your case. No, the other test , if its CA 125 , will not show a higher value.

The National Cancer Institute (NCI) recommends that high-risk women seek advice from their physicians and consider having annual ultrasonographic examinations and annual CA125 testing, as well as consider oophorectomy or participation in a clinical trial.

Thanks.

---

Brief Answer:
EXPLAINED

Detailed Answer:
hello,

The same test has different lab kits and have different reference ranges. for example the RBS range in my hospital s blood sugar kit in XXXXXXX number is 165, but in other labs its 185.
I assure you , if its within range, you don't need to worry.

CA125 is a glycoprotein commonly produced by the endometrium. Serum CA125 is widely useful as a marker for ovarian cancer screening, with 35 U/mL the generally accepted upper limit of normal. CA125 is known to fluctuate with vaginal bleeding and menopausal status, as its been demonstrated in many trials and studies. ITS A CORRELATION. The cyclic pattern of menses is halted and the hormonal irregularity leads to less predictable values and less constant results.


LET ME KNOW IF YOU HAVE ANY QUERY
THANKS

---